Aboriginal way of life and cancer diagnosis

Aboriginal way of life and cancer diagnosis

VJOncology

3 years
550 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Roslyn Weetra, an Aboriginal Elder and cancer survivor, discusses her experience with cancer being a member of the Australian aboriginal community. She was diagnosed with non-Hodgkins lymphoma and required hospital treatment. At the beginning of her treatment she mentions not understanding what some of the medical jargon meant, as well as difficulty in understanding how the cancer was going to impact her. Referring to her aboriginal culture, cancer treatment, including chemicals and non-traditional healing remedies, was an uncomfortable scenario for her. Ms. Weetra also mentions there being a lack of information that she could access at mainstream hospitals. Jasmine Micklem, PhD, of the South Australian Health and Medical Research Institute, Adelaide, Australia, follows on to mention that the aboriginal cancer care coordinators play a key role in helping people navigate the system, however, they are not always available at all of the hospitals. This can become a difficulty, especially for those living in remote areas where English may not be their first language. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.
Up Next Autoplay
BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
Category: Acute Lymphoblastic Leukemia
1 Views
VJOncology 1 year
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Category: General
820 Views
VJOncology 1 year
Patient symptom and experience trackers
Patient symptom and experience trackers
Category: General
588 Views
VJOncology 1 year
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
Category: General
581 Views
VJOncology 1 year
The switch to biosimilar rituximab at UCH: 12 months on
The switch to biosimilar rituximab at UCH: 12 months on
Category: Lymphoma
562 Views
VJOncology 1 year
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Category: General
368 Views
VJOncology 1 year
Visibility of Oncology Pharmacists to patients
Visibility of Oncology Pharmacists to patients
Category: Other
265 Views
VJOncology 1 year
Smart app to allow patients to manage their side effects independently
Smart app to allow patients to manage their side effects independently
Category: Breast Cancer
80 Views
VJOncology 1 year
cancer-druginteractions.org: a comprehensive tool for HCPs
cancer-druginteractions.org: a comprehensive tool for HCPs
Category: Other
39 Views
VJOncology 1 year
The emergence of mixed speciality oncology
The emergence of mixed speciality oncology
Category: Other
67 Views
VJOncology 1 year